Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)

• Status: Recruiting
• Trial end date: 2020-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate long term response of sulfonylurea and glucose control in children with diabetes due to mutations in ABCC8 that have been switched from insulin injections to sulfonylurea tablets.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Haukeland University Hospital
• Collaborators: Hôpital Necker-Enfants Malades; Institut National de la Santé Et de la Recherche Médicale, France; Royal Devon and Exeter NHS Foundation Trust; University of Bergen; University of Exeter; University of Rome Tor Vergata
• Treatments: Glyburide

Criteria

Inclusion Criteria:

• Permanent diabetes due to a mutation in ABCC8 (SUR1)

• Patients successfully transferred from insulin to sulfonylurea

• Transferred to sulfonylurea treatment before November 1, 2006 (ie 9 years off insulin)

• Willing and able to provide informed consent (parents if younger than 16 years of age)

Exclusion Criteria:

• Permanent diabetes not due to a mutation in ABCC8 (SUR1)

• Patients not successfully transferred from insulin to sulfonylurea

• Transferred to sulfonylurea treatment after November 1, 2006 (ie les than 9 years off insulin)

• Not willing or able to provide informed consent (parents if younger than 16 years of age)